Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11096-020-01049-6 http://scihub22266oqcxt.onion/10.1007/s11096-020-01049-6 32382873!7203261!32382873     free     free     free       Int+J+Clin+Pharm 2020 ; 42 (3): 833-836 Nephropedia Template TP {{tp|p=32382873|t=2020. Covid-19 and drug therapy, what we learned |pdf=|usr=}}{{32382873}} gab.com Text Covid-19 and drug therapy, what we learned JO: Int J Clin Pharm http://www.kidney.de/pget.php?&tw=1&pmid=32382873 #FOAvip COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge. Twit Text FOAVip Covid-19 and drug therapy, what we learned ????Int J Clin Pharm http://www.kidney.de/pget.php?&tw=1&pmid=32382873 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32382873 #FOAvip English Wikipedia <ref>{{Cite pmid|32382873}}</ref> Covid-19 and drug therapy, what we learned #MMPMID32382873 Provenzani A; Polidori P Int J Clin Pharm 2020[Jun]; 42 (3): 833-836 PMID32382873show ga COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge. |Antiviral Agents/pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |China[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH]Covid-19 and drug therapy, what we learned (epmc).pdf DeepDyve Pubget Overpricing